348 results on '"Afzali, Anita"'
Search Results
2. Indications and safety of newer IBD treatments in the older patient
3. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
4. Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
5. Surgery for Crohn’s Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective Cohorts
6. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies
7. Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare
8. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 G 3 PHASE 3 STUDIES
9. Surgery for Crohn’s Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts
10. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
11. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
12. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
13. Pregnancy Outcomes After Exposure to Certolizumab Pegol
14. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
15. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
16. Women’s Health and Ulcerative Colitis
17. Clinical long-term outcomes of patient-reported outcomes in the prospective real-world Tofacitinib Response in Ulcerative Colitis (TOUR) registry
18. S26 Clinical Practice Experience With Subcutaneous Vedolizumab for the Treatment of Patients With Ulcerative Colitis and Crohn’s Disease
19. Predicting Post-operative Complications in Crohn’s Disease: an Appraisal of Clinical Scoring Systems and the NSQIP Surgical Risk Calculator
20. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
21. S847 Efficacy of Guselkumab in Patients With Moderately to Severely Active Crohn’s Disease Not in Clinical Response at Week 12: Results From the GALAXI 1 Study
22. S851 Efficacy and Safety of Guselkumab for Crohn’s Disease Through 3 Years: GALAXI-1 Long-Term Extension
23. S1027 Impact of Prior Biologic Exposure on the Durability of 3-Year Continuous Ozanimod Treatment
24. S1774 Women in GI: Empowered Women Empower Women—Impact of the Second Annual Scrubs and Heels Summit
25. S977 Health Disparities in the Care of Patients With Inflammatory Bowel Disease: A Focus on Preventive Care & the Patient Perspective
26. S852 Long-Term Clinical and Endoscopic Outcomes in True North Week 52 Clinical Remitters Over 3 Years of Treatment With Ozanimod: An Interim Analysis of the True North Open-Label Extension Study
27. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
28. A women-focused matrix mentorship programme in gastroenterology
29. Opioid Use Is Associated With Higher Health Care Costs and Emergency Encounters in Inflammatory Bowel Disease
30. Inflammatory Bowel Disease in the Baby to Baby Boomer: Pediatric and Elderly Onset of IBD
31. Oral and Parenteral Corticosteroid Therapy in Ulcerative Colitis
32. Acute Myelogenous Leukemia as a Rare Cause of Duodenal Ulcers
33. Inflammatory bowel disease during pregnancy: management of a disease flare or remission
34. To the Editors: Index Severity Score and Early Readmission Predicts Increased Mortality in Crohn’s Disease Patients
35. Index Severity Score and Early Readmission Predicts Increased Mortality in Ulcerative Colitis Patients
36. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled Trial
37. S76 An Interim Analysis of 2 Years of Continuous Ozanimod Treatment From the True North Open-Label Extension Study
38. S1 Sarcopenia Is Associated With Social Determinants of Health in Patients With Inflammatory Bowel Disease
39. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
40. S799 Health-Related Quality of Life with Guselkumab Induction and Maintenance Therapy as Measured by PROMIS-29: Results Through Week 48 of Phase 2 GALAXI 1 Study
41. S810 Efficacy Outcomes by Symptom-Based Response Status After Induction: Week-48 Results from the GALAXI 1 Trial of Guselkumab in Crohn’s Disease
42. S731 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Baseline Endoscopic Disease Distribution: A Post Hoc Analysis of the Phase 3 True North Study
43. S757 Efficacy and Safety of 2 Years of Continuous Ozanimod Treatment: Interim Analysis of the True North Open-Label Extension Study
44. S2764 Racial and Ethnic Differences in Diagnosed Prevalence, Specialist Visits, and Treatment Utilization of Inflammatory Bowel Disease: Retrospective Analysis of U.S. Claims Data
45. S1493 Impostor Phenomenon and Microaggression Education and Self-Assessment in Female Healthcare Professionals in the Field of Gastroenterology
46. S938 Gender-Based Differences in Sarcopenia Screening With the SARC-F Questionnaire in Inflammatory Bowel Disease
47. S876 Efficacy of Deucravacitinib, an Oral, Selective, TYK2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis and Prior Exposure to Biologic Therapy: Subanalysis From the Phase 2 LATTICE-UC Study
48. Gender barriers are worsening women's access to health care in Afghanistan
49. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: A single academic center case series
50. Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.